![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
Vol. 58, Issue 4, 870-875, October 2000
Human Genome Research, Schering-Plough Research Institute,
Kenilworth, New Jersey
Neuromedin U (NmU) is a 25 amino acid peptide prominently expressed in
the upper gastrointestinal (GI) tract and central nervous system. It is
highly conserved throughout evolution and induces smooth muscle
contraction in a variety of species. Our understanding of NmU biology
has been limited because the identity of its receptor was unknown. Here
we demonstrate that GPR66/FM-3 is specifically stimulated by NmU,
causing the mobilization of intracellular calcium. This response was
dose-dependent (EC50 = 10 nM) and specific in
that none of over 1000 ligands tested, including other neuromedins (NmB, C, L, K, N), induced a calcium flux in GPR66/FM-3-transfected cells. The GPR66/FM-3 mRNA is prominently expressed in the upper GI
tract of humans, as is the mRNA for NmU, consistent with role for this
receptor-ligand pair in regulating the function of this organ system.
In addition, we show that whereas neuromedin U is expressed by
monocytes and dendritic cells, GPR66/FM-3 is expressed by T cells and
NK cells. These data suggest a previously unrecognized role for NmU as
an immunoregulatory molecule.
This article has been cited by other articles:
|
|
 |
|
  J. D. Mitchell, J. J. Maguire, R. E. Kuc, and A. P. Davenport Expression and vasoconstrictor function of anorexigenic peptides neuromedin U-25 and S in the human cardiovascular system Cardiovasc Res, November 26, 2008; (2008) cvn302v2. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. J. Brighton, A. Wise, N. B. Dass, and G. B. Willars Paradoxical Behavior of Neuromedin U in Isolated Smooth Muscle Cells and Intact Tissue J. Pharmacol. Exp. Ther., April 1, 2008; 325(1): 154 - 164. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Zeng, A. Gragerov, J. G. Hohmann, M. N. Pavlova, B. A. Schimpf, H. Xu, L.-J. Wu, H. Toyoda, M.-G. Zhao, A. D. Rohde, et al. Neuromedin U Receptor 2-Deficient Mice Display Differential Responses in Sensory Perception, Stress, and Feeding Mol. Cell. Biol., December 15, 2006; 26(24): 9352 - 9363. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Moriyama, S. Fukuyama, H. Inoue, T. Matsumoto, T. Sato, K. Tanaka, I. Kinjyo, T. Kano, A. Yoshimura, and M. Kojima The neuropeptide neuromedin U activates eosinophils and is involved in allergen-induced eosinophilia Am J Physiol Lung Cell Mol Physiol, May 1, 2006; 290(5): L971 - L977. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Moriyama, T. Sato, H. Inoue, S. Fukuyama, H. Teranishi, K. Kangawa, T. Kano, A. Yoshimura, and M. Kojima The neuropeptide neuromedin U promotes inflammation by direct activation of mast cells J. Exp. Med., July 18, 2005; 202(2): 217 - 224. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T J Kowalski, B D Spar, L Markowitz, M Maguire, A Golovko, S Yang, C Farley, J A Cook, G Tetzloff, L Hoos, et al. Transgenic overexpression of neuromedin U promotes leanness and hypophagia in mice J. Endocrinol., April 1, 2005; 185(1): 151 - 164. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. N. Johnson, E. R. Appelbaum, D. C. Carptenter, R. F. Cox, J. Disa, J. J. Foley, S. K. Ghosh, D. P. Naselsky, M. A. Pullen, H. M. Sarau, et al. Neuromedin Elicits Cytokine Release in Murine Th2-Type T Cell Clone D10.G4.1 J. Immunol., December 15, 2004; 173(12): 7230 - 7238. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. J. Brighton, P. G. Szekeres, A. Wise, and G. B. Willars Signaling and Ligand Binding by Recombinant Neuromedin U Receptors: Evidence for Dual Coupling to G{alpha}q/11 and G{alpha}i and an Irreversible Ligand-Receptor Interaction Mol. Pharmacol., December 1, 2004; 66(6): 1544 - 1556. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. J. Brighton, P. G. Szekeres, and G. B. Willars Neuromedin U and Its Receptors: Structure, Function, and Physiological Roles Pharmacol. Rev., June 1, 2004; 56(2): 231 - 248. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. R. Ivanov, C. B. Lawrence, P. J. Stanley, and S. M. Luckman Evaluation of Neuromedin U Actions in Energy Homeostasis and Pituitary Function Endocrinology, October 1, 2002; 143(10): 3813 - 3821. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. L. Morse, J. Behan, T. M. Laz, R. E. West Jr., S. A. Greenfeder, J. C. Anthes, S. Umland, Y. Wan, R. W. Hipkin, W. Gonsiorek, et al. Cloning and Characterization of a Novel Human Histamine Receptor J. Pharmacol. Exp. Ther., March 1, 2001; 296(3): 1058 - 1066. [Abstract] [Full Text]
|
|
|
|
 |
|
 L. Shan, X. Qiao, J. H. Crona, J. Behan, S. Wang, T. Laz, M. Bayne, E. L. Gustafson, F. J. Monsma Jr., and J. A. Hedrick Identification of a Novel Neuromedin U Receptor Subtype Expressed in the Central Nervous System J. Biol. Chem., December 8, 2000; 275(50): 39482 - 39486. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
